Abstract: The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.
Abstract: Disclosed herein are compounds of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders, including those associated with inflammation and cancer.
Type:
Application
Filed:
July 20, 2020
Publication date:
February 11, 2021
Applicant:
REATA PHARMACEUTICALS, INC.
Inventors:
Xin JIANG, Christopher F. BENDER, Ha DO, Haizhou SUN, Melean VISNICK
Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
Type:
Grant
Filed:
July 31, 2019
Date of Patent:
January 26, 2021
Assignee:
REATA PHARMACEUTICALS, INC.
Inventors:
Xin Jiang, Christopher F. Bender, Melean Visnick
Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
Type:
Application
Filed:
February 10, 2020
Publication date:
July 30, 2020
Applicant:
REATA PHARMACEUTICALS, INC.
Inventors:
Eric ANDERSON, Xin JIANG, Melean VISNICK
Abstract: Disclosed are co-crystal forms of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3?-fluoro-[1,1?-biphenyl]-2-yl)ethyl)-acetamide and L-proline or D-proline, their pharmaceutical compositions, processes of manufacture, and methods of use for treating neurodegenerative disorders such as diabetic peripheral neuropathy.
Type:
Grant
Filed:
February 1, 2019
Date of Patent:
July 21, 2020
Assignee:
Reata Pharmaceuticals, Inc.
Inventors:
Xin Jiang, John Allen Walling, Melanie J. Bevill, Christopher S. Seadeek, Jared P. Smit
Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
Type:
Application
Filed:
December 3, 2019
Publication date:
July 2, 2020
Applicant:
REATA PHARMACEUTICALS, INC.
Inventors:
Eric ANDERSON, Gary L. BOLTON, Bradley CAPRATHE, Xin JIANG, Chitase LEE, William H. ROARK, Melean VISNICK
Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
Type:
Application
Filed:
July 31, 2019
Publication date:
April 30, 2020
Applicant:
REATA PHARMACEUTICALS, INC.
Inventors:
Xin JIANG, Christopher F. BENDER, Melean VISNICK
Abstract: Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit ROR? and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders.
Type:
Application
Filed:
December 16, 2017
Publication date:
April 30, 2020
Applicant:
REATA PHARMACEUTICALS, INC.
Inventors:
Xin JIANG, Christopher F. BENDER, Melean VISNICK, Martha R. HOTEMA, Zachary S. SHELDON, Chitase LEE, Bradley William CAPRATHE, Gary BOLTON, Brian KORNBERG
Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
Type:
Grant
Filed:
August 28, 2018
Date of Patent:
February 11, 2020
Assignee:
REATA PHARMACEUTICALS, INC.
Inventors:
Eric Anderson, Xin Jiang, Melean Visnick
Abstract: Disclosed herein are novel C17-alkanediyl and alkenediyl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
Type:
Grant
Filed:
February 15, 2017
Date of Patent:
December 10, 2019
Assignee:
REATA PHARMACEUTICALS, INC.
Inventors:
Christopher F. Bender, Xin Jiang, Eric Anderson, Melean Visnick
Abstract: The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.
Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
Type:
Grant
Filed:
January 3, 2018
Date of Patent:
September 3, 2019
Assignee:
REATA PHARMACEUTICALS, INC.
Inventors:
Xin Jiang, Christopher F. Bender, Melean Visnick
Abstract: The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolone methyl.
Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
Type:
Grant
Filed:
June 6, 2017
Date of Patent:
October 9, 2018
Assignee:
REATA PHARMACEUTICALS, INC.
Inventors:
Eric Anderson, Xin Jiang, Melean Visnick
Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
Type:
Application
Filed:
January 4, 2018
Publication date:
September 20, 2018
Applicant:
REATA PHARMACEUTICALS, INC.
Inventors:
Eric ANDERSON, Gary L. BOLTON, Bradley CAPRATHE, Xin JIANG, Chitase LEE, William H. ROARK, Melean VISNICK
Abstract: This invention provides novel compounds comprising the following anti-inflammatory pharmacore: wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
Type:
Application
Filed:
October 24, 2017
Publication date:
August 23, 2018
Applicant:
REATA PHARMACEUTICALS, INC.
Inventors:
Eric ANDERSON, Gary L. BOLTON, Deborah A. FERGUSON, Xin JIANG, Robert M. KRAL, JR., Patrick M. O'BRIEN, Melean VISNICK
Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
Type:
Application
Filed:
January 3, 2018
Publication date:
August 23, 2018
Applicant:
REATA PHARMACEUTICALS, INC.
Inventors:
Xin JIANG, Christopher F. BENDER, Melean VISNICK
Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.
Type:
Application
Filed:
August 14, 2017
Publication date:
June 14, 2018
Applicants:
REATA PHARMACEUTICALS, INC., TRUSTEES OF DARTMOUTH COLLEGE
Inventors:
Michael B. SPORN, Karen T. LIBY, Gordon W. GRIBBLE, Tadashi HONDA, Robert M. Kral, Colin J. MEYER
Abstract: Disclosed herein are compounds of the formula: (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer.
Type:
Application
Filed:
February 12, 2016
Publication date:
May 10, 2018
Applicant:
REATA PHARMACEUTICALS, INC.
Inventors:
Xin JIANG, Bradley William CAPRATHE, Chitase LEE, Gary BOLTON, Christopher F. BENDER, Melean VISNICK
Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
Type:
Grant
Filed:
November 11, 2016
Date of Patent:
February 13, 2018
Assignee:
REATA PHARMACEUTICALS, INC.
Inventors:
Xin Jiang, Christopher F. Bender, Melean Visnick